Synbio Tech Inc (1295) AI Stock Analysis

Synbio Tech Inc

(TPEx:1295)

Select Model

Rating:59Neutral

Price Target:TWD 47.00▲(12.17% Upside)

Action:initiatedcoverage

Date:11/09/26

The score reflects a profitable, growing specialty biotech whose financial profile has become stretched. Durable gross margins above 50% and steady revenue and earnings growth are offset by slowing momentum, compressing operating margins, debt-to-equity now above 1.0, and a large free cash flow deficit driven by heavy capacity investment and weak operating cash conversion. Technicals reinforce caution, with the shares trading well below all key moving averages and a negative MACD, though an oversold stochastic hints at potential short-term stabilisation. The main offset is valuation: a P/E near 10.7, a dividend yield close to 6.7% and very low beta provide downside support and income, keeping the overall score in moderate territory rather than lower.

Positive Factors

Synthetic biology platformThe company’s synthetic biology and industrial fermentation capabilities support differentiated production of bio-based ingredients across nutrition, food/feed, and industrial applications. This platform can provide a durable foundation for serving multiple end markets and extending product opportunities over time.

Negative Factors

Weak cash conversionThe sharp deterioration in operating cash flow and deeply negative 2025 free cash flow show that reported profits are translating into cash less effectively. Persistent weakness would increase funding needs, constrain reinvestment, and reduce flexibility around capital spending.

Synbio Tech Inc (1295) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.60B
Dividend Yield: 7.14%
Average Volume (3M): 35.08K
Price to Earnings (P/E): 10.2
Beta (1Y): 0.20
Revenue Growth: -5.28%
EPS Growth: -27.33%
Country: TW
Employees: 92
Sector: General
Sector Strength: 55
Industry: Biotechnology

Synbio Tech Inc Business Overview & Revenue Model

Company Description

Synbio Tech Inc. operates as a biotechnology enterprise, primarily focusing on the development and production of probiotics and their various applications. The company also handles the marketing and distribution of several products in China, such as...

Synbio Tech Inc Financial Statement Overview

Summary

Synbio Tech combines an attractive income statement with a strained funding and cash profile. Revenue has expanded from about NT$737 million in 2020 to roughly NT$1.04 billion, with gross margin holding near 53% and net margin near 17% — but growth has slowed to mid-single digits and operating margin compressed from about 24% to 19%. The balance sheet is expanding rapidly on debt, with total debt rising from roughly NT$954 million to NT$1.39 billion and debt-to-equity moving above 1.0, while ROE softened to about 13%. Cash flow is the weakest element: operating cash flow fell to roughly NT$143 million, covering only about 22% of net income, and capital spending near NT$700 million drove free cash flow to about -NT$560 million. The capacity investment may support future growth, but near-term financial flexibility is limited.

Income Statement

71Positive

Balance Sheet

57Neutral

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Mar 2024	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.01B	1.04B	989.48M	823.30M	739.33M	855.79M
Gross Profit	495.09M	555.20M	540.84M	418.75M	361.33M	446.18M
EBITDA	261.05M	277.49M	316.35M	230.54M	200.66M	267.96M
Net Income	142.06M	175.97M	170.13M	113.27M	92.52M	159.97M
Balance Sheet
Total Assets	3.23B	3.09B	2.34B	1.89B	1.68B	1.53B
Cash, Cash Equivalents and Short-Term Investments	500.73M	376.23M	469.39M	346.74M	416.46M	393.45M
Total Debt	1.65B	1.39B	953.81M	731.77M	628.79M	506.37M
Total Liabilities	1.92B	1.72B	1.27B	943.27M	779.07M	669.93M
Stockholders Equity	1.31B	1.33B	1.08B	942.97M	897.68M	863.17M
Cash Flow
Free Cash Flow	-291.62M	-559.72M	-49.41M	-113.77M	-33.18M	218.26M
Operating Cash Flow	183.48M	143.35M	261.54M	213.93M	187.09M	262.88M
Investing Cash Flow	-599.66M	-838.87M	-313.21M	-137.17M	-203.43M	-101.52M
Financing Cash Flow	279.93M	492.20M	166.03M	49.16M	59.80M	-35.73M

Synbio Tech Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1295 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4911	72Outperform	TWD 1.74B	18.66	―	4.66%	-26.73%	-34.96%
TW:1294	67Neutral	TWD 1.62B	11.43	―	6.70%	20.43%	4.47%
TW:4148	60Neutral	TWD 1.96B	10.66	―	3.40%	15.66%	31.51%
TW:1295	59Neutral	TWD 1.58B	10.17	―	7.14%	-5.28%	-27.33%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4127	40Underperform	TWD 1.65B	23.91	―	―	52.12%	―

* General Sector Average

Performance Comparison

TW:1295 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1295	Synbio Tech Inc	41.90	-52.13	-55.44%
TW:1294	Hantech Bio-Technology Co., Ltd.	44.80	-14.14	-23.99%
TW:4127	Tien Liang Biotech Co., Ltd.	36.15	4.40	13.86%
TW:4148	All Cosmos Bio-Tech Holding Corp.	29.40	-10.25	-25.86%
TW:4911	G&E Herbal Biotechnology Co., Ltd.	25.00	-18.60	-42.66%
TW:7837	Creative Life Science Co Ltd	73.40	-35.96	-32.88%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Synbio Tech Inc AI Stock Analysis